Literature DB >> 27449186

Long-Term Course After Adaptive Multimodal Treatment for Children With ADHD: An 8-Year Follow-Up.

Manfred Döpfner1, Elena Ise1, Dieter Breuer1, Christiane Rademacher1, Tanja Wolff Metternich-Kaizman1, Stephanie Schürmann1.   

Abstract

Objective: This study reassessed adolescents and young adults (15-22 years old) who received individually tailored multimodal treatment for ADHD (behavior therapy and/or stimulant medication) during childhood 6 to 12 years after treatment (M = 8.8 years, SD = 1.6). Method: All participants (N = 75) provided information about their social functioning. Most parents (83%) completed behavior rating scales.
Results: Participants demonstrated significant improvement in behavior during the follow-up period with effect sizes on ADHD symptoms of d = 1.2 and 68% of the former patients in the normal range at follow-up. Participants reported elevated rates of grade retention (51%), school dropout (13%), special education service use (17%), school change (47%), and conviction (16%), but few were unemployed (4%).
Conclusion: This study provides evidence that the effects of individually tailored multimodal treatment for ADHD in childhood are maintained into adolescence and young adulthood. No hints could be found that continued medication results in a more favorable long-term outcome.

Entities:  

Keywords:  ADHD; behavior therapy; long-term effects; medical management; multimodal treatment

Mesh:

Substances:

Year:  2016        PMID: 27449186     DOI: 10.1177/1087054716659138

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  5 in total

1.  ESCAschool study: trial protocol of an adaptive treatment approach for school-age children with ADHD including two randomised trials.

Authors:  Manfred Döpfner; Christopher Hautmann; Christina Dose; Tobias Banaschewski; Katja Becker; Daniel Brandeis; Martin Holtmann; Thomas Jans; Carolin Jenkner; Sabina Millenet; Tobias Renner; Marcel Romanos; Elena von Wirth
Journal:  BMC Psychiatry       Date:  2017-07-24       Impact factor: 3.630

2.  Individualised short-term therapy for adolescents impaired by attention-deficit/hyperactivity disorder despite previous routine care treatment (ESCAadol)-Study protocol of a randomised controlled trial within the consortium ESCAlife.

Authors:  Julia Geissler; Thomas Jans; Tobias Banaschewski; Katja Becker; Tobias Renner; Daniel Brandeis; Manfred Döpfner; Christina Dose; Christopher Hautmann; Martin Holtmann; Carolin Jenkner; Sabina Millenet; Marcel Romanos
Journal:  Trials       Date:  2018-04-27       Impact factor: 2.279

3.  Sequential treatment of ADHD in mother and child (AIMAC study): importance of the treatment phases for intervention success in a randomized trial.

Authors:  Christopher Hautmann; Manfred Döpfner; Josepha Katzmann; Stephanie Schürmann; Tanja Wolff Metternich-Kaizman; Charlotte Jaite; Viola Kappel; Julia Geissler; Andreas Warnke; Christian Jacob; Klaus Hennighausen; Barbara Haack-Dees; Katja Schneider-Momm; Alexandra Philipsen; Swantje Matthies; Michael Rösler; Wolfgang Retz; Alexander von Gontard; Esther Sobanski; Barbara Alm; Sarah Hohmann; Alexander Häge; Luise Poustka; Michael Colla; Laura Gentschow; Christine M Freitag; Katja Becker; Thomas Jans
Journal:  BMC Psychiatry       Date:  2018-12-13       Impact factor: 3.630

4.  Impact of stimulant medication on behaviour and executive functions in children with attention-deficit/hyperactivity disorder.

Authors:  Tasmia Hai; Hanna A Duffy; Julie Anne Lemay; Jean François Lemay
Journal:  World J Clin Pediatr       Date:  2022-01-09

5.  Predicting delinquent behavior in young adults with a childhood diagnosis of ADHD: results from the Cologne Adaptive Multimodal Treatment (CAMT) Study.

Authors:  Dieter Breuer; Elena von Wirth; Janet Mandler; Stephanie Schürmann; Manfred Döpfner
Journal:  Eur Child Adolesc Psychiatry       Date:  2020-12-04       Impact factor: 5.349

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.